NO991691L - Cancer immunoterapi ved Õ bruke tumorceller kombinert med blandede lymfosytter - Google Patents

Cancer immunoterapi ved Õ bruke tumorceller kombinert med blandede lymfosytter

Info

Publication number
NO991691L
NO991691L NO991691A NO991691A NO991691L NO 991691 L NO991691 L NO 991691L NO 991691 A NO991691 A NO 991691A NO 991691 A NO991691 A NO 991691A NO 991691 L NO991691 L NO 991691L
Authority
NO
Norway
Prior art keywords
tumor
stimulated
lymphocytes
allogeneic
cancer immunotherapy
Prior art date
Application number
NO991691A
Other languages
English (en)
Other versions
NO991691D0 (no
Inventor
John C Hiserodt
James A Thompson
Gale A Granger
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of NO991691D0 publication Critical patent/NO991691D0/no
Publication of NO991691L publication Critical patent/NO991691L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Denne oppfinnelsen omfatter cellulære vaksiner og metoder for å bruke dem i cancer immunoterapi, spesielt hos mennesker. Vaksinene omfatter stimulerte lymfosytter allogene til individet som blir behandlet, sammen med en kilde av tumorassosierte antigen. Allogene lymfosytter kan bli stimulert ved å kombinere eller samdyrke dem med leukosytter ervervet fra individet som skal bli behandlet eller danne andre tredjeparts donorer. Tumorantigen kan bli tilveiebragt i form av primær tumorceller, tumorcellelinjer eller tumorekstrakter fremstilt fra individet. Stimulerte allogene lymfosytter og tumorantigen blir kombinert og administrert på et sted fjernt fra primærtumoren for å "prime" eller "booste" en systematisk cellulær antitumorimmunrespons. Denne tilnærmingen overvinner den naturlige motstridige evnen til immunsystemet for stimulering av tumorantigener som danner en vertsrespons og potensielt forbedrer det kliniske utkommet.
NO991691A 1996-10-11 1999-04-09 Cancer immunoterapi ved Õ bruke tumorceller kombinert med blandede lymfosytter NO991691L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2854896P 1996-10-11 1996-10-11
PCT/US1997/018718 WO1998016238A2 (en) 1996-10-11 1997-10-10 Cancer immunotherapy using tumor cells combined with mixed lymphocytes

Publications (2)

Publication Number Publication Date
NO991691D0 NO991691D0 (no) 1999-04-09
NO991691L true NO991691L (no) 1999-06-09

Family

ID=21844058

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991691A NO991691L (no) 1996-10-11 1999-04-09 Cancer immunoterapi ved Õ bruke tumorceller kombinert med blandede lymfosytter

Country Status (13)

Country Link
US (1) US6207147B1 (no)
EP (1) EP0930887B1 (no)
JP (1) JP2001509135A (no)
KR (1) KR20000049096A (no)
CN (1) CN1237909A (no)
AR (1) AR004445A1 (no)
AT (1) ATE229810T1 (no)
AU (1) AU743855B2 (no)
BR (1) BR9712988A (no)
CA (1) CA2267157C (no)
DE (1) DE69718029T2 (no)
NO (1) NO991691L (no)
WO (1) WO1998016238A2 (no)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361332B2 (en) 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US20080220025A1 (en) * 1995-03-17 2008-09-11 James Thompson Treating Tumors Using Implants Comprising Combinations of Allogeneic Cells
WO1998048000A2 (en) * 1997-04-23 1998-10-29 The Regents Of The University Of California A cell strain with activated anti-cancer cytotoxic activity
EP1037643B1 (en) 1997-10-10 2003-12-03 Meyer Pharmaceuticals, LLC Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy
AU9794698A (en) 1997-10-10 1999-05-03 Regents Of The University Of California, The Enhanced immunogenic cell populations prepared using h2 receptor antagonists
CA2346769C (en) * 1997-10-10 2004-09-14 The Regents Of The University Of California Implants comprising combinations of allogeneic cells for use in cancer treatment
JP4389039B2 (ja) * 1998-04-09 2009-12-24 株式会社リンフォテック アロジェニックな活性化ｃｄ４陽性細胞を主成分とする医薬組成物、およびその製造方法、ならびに該医薬組成物調製用キット
US7666609B1 (en) 1998-12-01 2010-02-23 Shanghai Cp Guojian Pharmaceutical Co. Ltd. Method and composition for diagnosis of melanocytic lesions
CN100425287C (zh) * 1999-02-09 2008-10-15 理化学研究所 肿瘤疫苗
CA2404388C (en) 2000-04-01 2010-06-15 Onyvax Limited New prostate cell lines
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
DE10043437A1 (de) * 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
US20040191246A1 (en) 2003-02-26 2004-09-30 Connelly Patrick R. Process for in vivo treatment of specific biological targets in bodily fluid
US7723111B2 (en) * 2001-03-09 2010-05-25 The United States Of America As Represented By The Department Of Health And Human Services Activated dual specificity lymphocytes and their methods of use
HUP0400882A3 (en) * 2001-05-11 2011-01-28 Wellstat Biologics Corp Oncolytic virus therapy
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
EP1293205A1 (en) * 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
DE60225046T2 (de) * 2001-11-27 2009-07-09 Nexyte Ab Produktion eukaryontischer proteine und nukleinsäuremoleküle in c. elegans
KR20020060643A (ko) * 2002-06-04 2002-07-18 김진경 타인의 면역시스템을 이용하는 암의 치료 방법
PL214283B1 (pl) * 2002-08-08 2013-07-31 Baylor College Medicine Sposób izolacji komórek T, sposób wytwarzania autologicznej szczepionki komórek T, autologiczna szczepionka komórek T, zastosowanie autologicznej szczepionki komórek T
US7571817B2 (en) * 2002-11-06 2009-08-11 Varco I/P, Inc. Automatic separator or shaker with electromagnetic vibrator apparatus
KR20040094635A (ko) * 2003-05-02 2004-11-10 주식회사 엠디바이오알파 항종양 활성의 유도를 위한 종양 백신의 제조방법 및그것을 함유하고 있는 약제 조성물
US7811983B2 (en) * 2003-06-11 2010-10-12 The University Of Chicago Increased T-cell tumor infiltration and eradication of metastases by mutant light
ATE382372T1 (de) 2003-06-11 2008-01-15 Univ Chicago Erhöhte t-zell tumor-eindringung durch light- mutanten
US20050019336A1 (en) 2003-07-23 2005-01-27 Dalgleish Angus George Human prostate cell lines in cancer treatment
US7696322B2 (en) * 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
CA2542120C (en) * 2003-10-08 2018-07-10 Vet-Stem Inc. Methods of preparing and using stem cell compositions and kits comprising the same
US8029454B2 (en) 2003-11-05 2011-10-04 Baxter International Inc. High convection home hemodialysis/hemofiltration and sorbent system
US20050112684A1 (en) * 2003-11-21 2005-05-26 Eric Holzle Class I and Class II MHC Profiling for Social and Sexual Matching of Human Partners
CN1950518A (zh) 2004-02-03 2007-04-18 密执安州立大学董事会 表征、调节、诊断和治疗癌症的组合物和方法
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
US8257715B1 (en) 2004-08-26 2012-09-04 University Of Notre Dame Tissue vaccines and uses thereof
US9155789B2 (en) * 2005-04-25 2015-10-13 New York University Use of allogenic or syngenic major histocompatibility complex (MHC) molecules as universal adjuvants for vaccines against neoplastic disease, infection and autoimmune disease
US20090162405A1 (en) * 2006-12-14 2009-06-25 Yong Qian Proteinase-engineered cancer vaccine induces immune responses to prevent cancer and to systemically kill cancer cells
US8778362B2 (en) 2005-10-27 2014-07-15 University Of Notre Dame Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof
US9308252B2 (en) * 2005-10-27 2016-04-12 Cook Biotech, Inc. Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
US8802113B2 (en) * 2005-10-27 2014-08-12 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US8778360B2 (en) * 2005-10-27 2014-07-15 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US7723112B2 (en) * 2005-10-31 2010-05-25 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7723477B2 (en) * 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
WO2007053577A2 (en) 2005-10-31 2007-05-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US20080019961A1 (en) * 2006-02-21 2008-01-24 Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
US20070243192A1 (en) * 2006-02-21 2007-10-18 Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
PL2420833T3 (pl) * 2006-05-05 2016-03-31 Opexa Therapeutics Szczepionka z komórek T
PT2511301T (pt) 2006-08-04 2018-03-08 Medimmune Ltd Anticorpos humanos para erbb2
US7972594B2 (en) 2006-11-13 2011-07-05 Immunovative Therapies Ltd. Ablative immunotherapy
WO2008061392A1 (fr) * 2006-11-22 2008-05-29 Hua Liu Procédé de préparation de populations cellulaires présentant une réponse immunitaire antitumorale
US20080147007A1 (en) * 2006-12-19 2008-06-19 Toby Freyman Delivery device with pressure control
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
CA2676143A1 (en) 2007-01-26 2008-07-31 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
WO2008098183A2 (en) * 2007-02-08 2008-08-14 The University Of Chicago Combination therapy for treating cancer
US8263081B2 (en) 2007-05-14 2012-09-11 The University Of Chicago Antibody-light fusion products for cancer therapeutics
US8741315B2 (en) * 2007-09-12 2014-06-03 Yeda Research And Development Co. Ltd. Methods of treating tumors in immune-privileged sites
US8114276B2 (en) 2007-10-24 2012-02-14 Baxter International Inc. Personal hemodialysis system
US9283266B2 (en) * 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
RU2579897C2 (ru) 2008-09-26 2016-04-10 Онкомед Фармасьютикалс, Инк. Агенты, связывающие рецептор "frizzled", и их применение
AU2009308707A1 (en) * 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
PL2356462T3 (pl) 2008-11-11 2017-07-31 The Regents Of The University Of Michigan Kompozycje anty-CXCR1 oraz sposoby
CU23740A1 (es) * 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech Método de obtención de una formulación de antígenos del virus de la hepatitis b
CN102597222B (zh) * 2009-10-27 2015-07-15 因缪尼卡姆股份公司 用于增殖抗原特异性t细胞的方法
US8846059B2 (en) 2009-12-08 2014-09-30 University Of Notre Dame Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer
EP2510084B1 (en) * 2009-12-08 2020-02-05 The Board of Trustees of the University of Illionis Stem cell immune modulation methods of use and apparatus
US20110150934A1 (en) * 2009-12-18 2011-06-23 University Of Notre Dame Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
EP2548025A4 (en) 2010-03-17 2013-09-25 Univ Michigan USE OF PHOTOEPITOPES FOR PROFILING AN IMMUNE REACTION
KR20130043102A (ko) 2010-04-01 2013-04-29 온코메드 파마슈티칼스, 인크. 프리즐드-결합 작용제 및 그의 용도
WO2011129348A1 (ja) * 2010-04-13 2011-10-20 株式会社Ｒｅｉメディカル 癌組織由来細胞塊または癌細胞凝集塊から得られる癌治療用組成物およびそれを用いた免疫療法剤の製造方法ならびに免疫療法効果評価方法
US10350242B2 (en) 2011-05-03 2019-07-16 Immunovative Therapies Ltd. Methods for handling biological drugs containing living cells
NZ730355A (en) * 2011-05-24 2022-10-28 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Individualized vaccines for cancer
CN104284680A (zh) 2011-12-15 2015-01-14 芝加哥大学 使用对受体的亲和力增加的突变型light分子用于癌症治疗的方法和组合物
AU2013334790A1 (en) 2012-10-23 2015-04-30 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
EP3049155A1 (en) * 2013-09-27 2016-08-03 Vaccinogen International Partners, LP Autologous tumor vaccines and methods
SG11201703406YA (en) 2014-11-05 2017-05-30 Sloan Kettering Inst Cancer Methods of selecting t cell line and donor thereof for adoptive cellular therapy
US20180055920A1 (en) * 2015-03-12 2018-03-01 University Of Iowa Research Foundation Vaccine, therapeutic composition and methods for treating or inhibiting cancer
WO2016209816A1 (en) * 2015-06-26 2016-12-29 Memorial Sloan Kettering Cancer Center Methods of treating cmv retinitis by t cell therapy
US20170119820A1 (en) 2015-07-31 2017-05-04 Regents Of The University Of Minnesota Modified cells and methods of therapy
US11219645B2 (en) 2015-11-18 2022-01-11 Duke University Tumor infiltrating lymphocytes for treatment of cancer
CN110520530A (zh) 2016-10-18 2019-11-29 明尼苏达大学董事会 肿瘤浸润性淋巴细胞和治疗方法
US20200237904A1 (en) 2017-01-26 2020-07-30 Immune Therapeutics Inc. Methods and Compositions Useful for Treating Cancer
WO2019006418A2 (en) 2017-06-30 2019-01-03 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
KR102256337B1 (ko) * 2017-10-17 2021-05-26 (주)노터스생명과학 조직이식을 위한 세포배양액을 포함하는 면역억제제
US11446329B2 (en) 2017-11-01 2022-09-20 Restem Llc Natural killer cell adoptive transfer therapy for the elimination of senescent PBMCs, reduction of inflammatory cytokines and treatment of IBS
IL259392A (en) 2018-05-15 2018-08-01 Yeda Res & Dev Vaccination with cancer neo-antigens
FR3082730B1 (fr) 2018-06-21 2022-04-22 Med Inn Pharma Methode de resolution de l'inflammation pro-tumorale a l'aide d'une preparation pharmaceutique
WO2023196232A1 (en) * 2022-04-04 2023-10-12 University Of Florida Research Foundation, Inc. Method of characterizing tumors
CN114984199A (zh) * 2022-04-19 2022-09-02 苏州尔生生物医药有限公司 一种基于癌症特异性t细胞的细胞系统、淋巴细胞药物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192537A (en) 1984-03-30 1993-03-09 Cellcor Inc. Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
JP2639835B2 (ja) * 1988-11-30 1997-08-13 有限会社ジオリサーチ 免疫記憶細胞懸濁液の調製方法
US5229115A (en) * 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
JPH06121672A (ja) * 1992-10-13 1994-05-06 Cellcor Inc 免疫反応性細胞の製造
US5820872A (en) * 1992-11-18 1998-10-13 Yale University Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor
EP0688223A4 (en) 1993-03-12 1998-05-13 Cellcor Inc TITRATION METHOD -i (IN VITRO) FOR MEASURING THE DEGREE OF ACTIVATION OF IMMUNE CELLS
WO1995016775A1 (en) 1993-12-14 1995-06-22 Yajun Guo Tumor cell fusions and methods for use of such tumor cell fusions
US5759535A (en) 1994-05-13 1998-06-02 Research Corporation Technologies, Inc. Immunotherapeutic strategies for the treatment of cancer
WO1995034638A1 (en) * 1994-06-14 1995-12-21 The Board Of Trustees Of Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
DE4431401A1 (de) 1994-08-24 1996-02-29 Max Delbrueck Centrum Lebendvakzine gegen Tumorerkrankungen
EP0815204B1 (en) 1995-03-17 2006-09-06 The Regents Of The University Of California Method for treating tumors by alloactivated human donor lymphocytes
US6277368B1 (en) * 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine

Also Published As

Publication number Publication date
WO1998016238A2 (en) 1998-04-23
JP2001509135A (ja) 2001-07-10
CN1237909A (zh) 1999-12-08
AR004445A1 (es) 1998-12-16
AU4824297A (en) 1998-05-11
EP0930887A2 (en) 1999-07-28
CA2267157C (en) 2005-05-31
DE69718029D1 (de) 2003-01-30
DE69718029T2 (de) 2003-10-16
EP0930887B1 (en) 2002-12-18
WO1998016238A3 (en) 1998-09-11
CA2267157A1 (en) 1998-04-23
KR20000049096A (ko) 2000-07-25
NO991691D0 (no) 1999-04-09
BR9712988A (pt) 2000-10-24
AU743855B2 (en) 2002-02-07
US6207147B1 (en) 2001-03-27
ATE229810T1 (de) 2003-01-15

Similar Documents

Publication Publication Date Title
NO991691L (no) Cancer immunoterapi ved Õ bruke tumorceller kombinert med blandede lymfosytter
EP0789574A4 (en) METHOD AND DEVICES FOR IMMUNIZING A HOST AGAINST TUMOR ASSOCIATED ANTIGENS BY ADMINISTRATING NAKED POLYNUCLEOTIDES CODING TUMOR ASSOCIATED ANTIGEN PEPTIDES
ATE472339T1 (de) Dna-vakzine gegen tumorwachstum und anwendungsverfahren dafür
ATE389712T1 (de) Krebs immuntherapie mit semi-allogenen zellen
He et al. Antitumor efficacy of viable tumor vaccine modified by heterogenetic ESAT-6 antigen and cytokine IL-21 in melanomatous mouse
Zhang et al. Impact of dose, route, and composition on the immunogenicity of immune polyelectrolyte multilayers delivered on gold templates
Van Dinther et al. Comparison of protein and peptide targeting for the development of a CD169-based vaccination strategy against melanoma
Huber et al. Immmunotherapy of cancer: from vision to standard clinical practice
AU2005314271B2 (en) Alpha thymosin peptides as cancer vaccine adjuvants
Gregoire et al. Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia
Escribà-Garcia et al. Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma
Schultes et al. Monitoring of immune responses to CA125 with an IFN-γ ELISPOT assay
EP1229936B1 (de) Verwendung von anti-idiotypischen antikörpern als impfstoffe gegen krebs
Wagner et al. Induction and characterization of anti-tumor endothelium immunity elicited by ValloVax therapeutic cancer vaccine
Grzybowski et al. Novel dual arginase 1/2 inhibitor OATD-02 (OAT-1746) improves the efficacy of immune checkpoint inhibitors
Mellstedt et al. Ga733/EpCAM as a target for passive and active specific immunotherapy in patients with colorectal carcinoma
Durrant et al. Cancer vaccines entering Phase III clinical trials
CN111372656A (zh) 抗体依赖性细胞介导的细胞毒性(adcc)的增强
Bolli et al. Oncoantigens for an immune prevention of cancer.
Shimada et al. TNP-specific Lyt-2+ cytolytic T cell clones preferentially respond to TNP-conjugated epidermal cells.
Prat et al. Monoclonal antibodies against murine IFN-gamma abrogate in vivo tumor immunity against RSV-induced murine sarcomas.
Wen et al. In‐vivo immune responses to idiotypic VH complementarity‐determining region 3 peptide vaccination in B‐cell non‐Hodgkin's lymphoma
Schütz et al. MHC‐Ig induces memory T cell formation in vivo and inhibits tumour growth
EP0684831A4 (en) ALLOGENIC VACCINE AND METHOD FOR SYNTHESIZING THE SAME.
Jin et al. The Epitope Basis of Embryonic Stem Cell‐Induced Antitumor Immunity against Bladder Cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application